Hematopoietic Stem Cell Transplants for Multiple Myeloma

References

• Barlogie B., Alexanian R., Jagannath S. Plasma cell dyscrasias. JAMA 1992; 268: 2946–2951
   PubMed Web of Science ®Google Scholar
• Barlogie B., Epstein J., Selvanayagam P., Alexanian R. Plasma cell myeloma—New biological insights and advances in therapy. Blood 1989; 73: 865–879
   PubMed Web of Science ®Google Scholar
• Kyle R.A. Long-term survival in multiple myeloma. N. Engl. J. Med. 1983; 308: 314–316
   PubMed Web of Science ®Google Scholar
• Gregory W.M., Richards M.A., Malpas J.S. Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma: An overview of published trials. J. Clin. Oncol. 1992; 10: 334–342
   PubMed Web of Science ®Google Scholar
• Durie B. G. M., Stock-Novack D., Salmon S.E., Finley P., Beckord J., Crowley J., Coltman C.A. Prognostic value of pretreatment serum β2 microglobulin in myeloma: A Southwest Oncology Group study. Blood 1990; 75: 823–830
   PubMed Web of Science ®Google Scholar
• Bataille R., Boccadoro M., Klein B., Durie B., Piled A. C-reactive protein and β-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80: 733–737
   PubMed Web of Science ®Google Scholar
• Greipp P.R., Lust J.A., O'Fallon W.M., Katemann J.A., Witzig T.E., Kyle R.A. Plasma cell labeling index and β2-mi-croglobulin predict survival independent of thymidine kinase and c-reactive protein in multiple myeloma. Blood 1993; 81: 3382–3387
   PubMed Web of Science ®Google Scholar
• San Miguel J.F., Garcia-Sanz R., Gonzalez M., Moro M.J., Hernandez J.M., Ortega F., Borrego D., Carnera M., Casanova F., Jimenez R., Portero J.A., Orfao A. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 1995; 85: 448–455
   PubMed Web of Science ®Google Scholar
• Ffrench M., Ffrench P., Remy F., Chapuis-Cellier C., Wolowiec D., Ville D., Bryon P.A. Plasma cell proliferation in monoclonal gammopathy: Relations with other biologic variables—diagnostic and prognostic significance. Am. J. Med. 1995; 98: 60–66
   PubMed Web of Science ®Google Scholar
• Dewald G.W., Kyle R.A., Hicks G.A., Greipp P.R. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 1985; 66: 380–390
   PubMed Web of Science ®Google Scholar
• Lai J.L., Zandecki M., Mary J.Y., Bernardi F., Izydorczyk V., Flactif M., Moret P., Jouet J.P., Bauters F., Facon T. Improved cytogenetics in multiple myeloma: A study of 151 patients including 117 patients at diagnosis. Blood 1995; 85: 2490–2497
   PubMed Web of Science ®Google Scholar
• Dimopoulos M.A., Barlogie B., Smith T.L., Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann. Intern. Med. 1991; 115: 931–935
   PubMed Web of Science ®Google Scholar
• Greipp P.R., Raymond N.M., Kyle R.A., O'Fallon W.M. Multiple myeloma: Significance of plasmablastic subtype in morphological classification. Blood 1985; 65: 305–310
   PubMed Web of Science ®Google Scholar
• Salmon S.E., Tesh D., Crowley J., Saeed S., Finley P., Milder M.S., Hutchins L.F., Coltman C.A., Bonnet J.D., Cheson B., Knost J.A., Samhouri A., Beckord J., Stock-Novack D. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: A Southwest Oncology Group study. J. Clin. Oncol. 1990; 8: 1575–1584
   PubMed Web of Science ®Google Scholar
• Cooper M.R., Dear K., McLntyre O.R., Ozer H., Ellerton J., Canellos G., Bemhardt B., Duggan D., Faragher D., Schiffer C. A randomized clinical trial comparing melphalan/pred-nisolone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: A cancer and leukemia group B study. J. Clin. Oncol. 1993; 11: 155–160
   PubMed Web of Science ®Google Scholar
• Blade J., Lopez-Guillermo A., Bosch F., Cervantes F., Reverter J.-C., Montserrat E., Rozman C. Impact of response to treatment on survival in multiple myeloma: Results in a series of 243 patients. Br. J. Haematol. 1994; 88: 117–121
   PubMed Web of Science ®Google Scholar
• MacLennan I. C. M., Chapman C., Dunn J., Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet 1992; 339: 200–205
   PubMed Web of Science ®Google Scholar
• Osterborg A., Bjorkholm M., Bjoreman M., Brenning F., Carlson K., Celsing F., Gahrton G., Grimfors G., Gyllenhammar H., Hast R., Johansson B., Juliusson G., Jammark M., Kimby E., Lerner R., Linder O., Merk K., Nilsson B., Ohrling M., Paul C., Simonsson B., Smedmyr B., Svedmyr E., Stalfelt A-M., Strander H., Uden A-M., Osby E., Mellstedt H. Natural inter-feron-a in combination with melphalan/prednisone versus melpha-lan/prednisone in the treatment of multiple myeloma stages II and III: A randomized study from the Myeloma Group of Central Sweden. Blood 1993; 81: 1428–1434
   PubMed Web of Science ®Google Scholar
• Boccadoro M., Marmont F., Tribalto M., Avvisati G., Andriani A., Barbui T., Cantonetti M., Carotenuto M., Camotti B., Dammacco F., Frieri R., Gallamini A., Gallone G., Giovangrossi P., Grignani F., Lauta V.M., Liberati M., Musto P., Neretto G., Petrucci M.T., Resegotti L., Pileri A., Mandelli F. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J. Clin. Oncol. 1991; 9: 444–448
   PubMed Web of Science ®Google Scholar
• Alexanian R., Barlogie B., Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am. J. Hematol. 1990; 33: 86–89
   PubMed Web of Science ®Google Scholar
• Alexanian R., Dimopoulos M.A., Delasalle K., Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992; 80: 887–890
   PubMed Web of Science ®Google Scholar
• Hata H., Xiao H., Petrucci M.T., Woodliff J., Chang R., Epstein J. Interleukin-6 gene expression in multiple myeloma: A characteristic of immature tumor cells. Blood 1993; 81: 3357–3364
   PubMed Web of Science ®Google Scholar
• Epstein J., Xiao H., Oba B.K. P-Glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood 1989; 74: 913–917
   PubMed Web of Science ®Google Scholar
• McElwain T.J., Powles R.L. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983; 822–824
   PubMed Web of Science ®Google Scholar
• Vesole D.H., Barlogie B., Jagannath S., Cheson B., Tricot G., Alexanian R., Crowley J. High-dose therapy for refractory multiple myeloma: Improved prognosis with better supportive care and double transplants. Blood 1994; 84: 950–956
   PubMed Web of Science ®Google Scholar
• Selby P., McElwain T., Mana A., Nandi A.C. Multiple myeloma treated with high-dose intravenous melphalan. Br. J. Haematoi. 1987; 66: 55–62
   PubMed Web of Science ®Google Scholar
• Cunningham D., Paz-Ares L., Gore M.E., Malpas J., Hickish T., Nicolson M., Meldrum M., Viner C., Milan S., Selby P.J., Normal A., Raymond J., Powles R. High-dose melphalan for multiple myeloma: long-term follow-up data. J. Clin. Oncol. 1994; 12: 764–768
   PubMed Web of Science ®Google Scholar
• Lokhorst H.M., Meuwissen O. J. A. T., Verdonck L.F., Dekker A.W. High-risk multiple myeloma treated with high-dose melphalan. J. Clin. Oncol. 1992; 10: 47–51
   PubMed Web of Science ®Google Scholar
• Cunningham D., Paz-Ares L., Milan S., Powles R., Nicolson M., Hickish T., Selby P., Treleavan J., Viner C., Malpas J., Slevin M., Findlay M., Raymond J., Gore M.E. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J. Clin. Oncol. 1994; 12: 759–763
   PubMed Web of Science ®Google Scholar
• Harousseau J-L., Attal M., Divine M., Mark G., Leblond V., Stoppa A-M., Bourhis J.-H., Caillot D., Boasson M., Abgrall J-F., Facon T., Linassier C., Cahn J-Y., Lamy T., Troussard X., Gratecos N., Pignon B., Auzanneau G., Bataille R. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of the French Registry on autologous transplantation in multiple myeloma. Blood 1995; 85: 3077–3085
   PubMed Web of Science ®Google Scholar
• Barlogie B., Jagannath S., Vesole D., Miller L., Cheson B., Bracy D., Tricot G. Total therapy (TT) for 202 newly diagnosed patients (PTS) with multiple myeloma (MM). Blood 1994; 84(Suppl 1)386a, (abstr)
   Google Scholar
• Speed D.E., Galton D. A. G., Swan A. Melphalan in the treatment of myelomatosis. Br. Med. J. 1964; 1: 1964–1969
   Google Scholar
• Zucchetti M., D'Incalci M., Willems Y., Cavalli F., Serra C. Lack of effect of cisplatin on IV L-PAM plasma pharmaco-kinetics in ovarian cancer patients. Cancer Chemother. Pharmacol. 1988; 22: 87–89
   PubMedGoogle Scholar
• Osterborg A., Ehrsson H., Eksborg S., Wallin I., Mellistedt H. Pharmacokinetics of oral melphalan in relation to renal function in multiple myeloma patients. Eur. J. Cancer Clin. Oncol. 1989; 25: 899–903
   PubMedGoogle Scholar
• Harousseau J.L., Milpied N., Laporte J.P., Collombat P., Facon T., Tigaud J.D., Casassus P., Guilhot F., Ifrah N., Gandhour C. Double-intensive therapy in high-risk multiple myeloma. Blood 1992; 79: 2827–2833
   PubMed Web of Science ®Google Scholar
• Tricot G., Alberts D.S., Barlogie B., Dorr R.T., Vesole D.H., Jagannath S., Meyers R., Roe D. High-dose melphalan pharmacokinetics in multiple myeloma, (submitted)
   Google Scholar
• Tricot G., Sawyer J., Jagannath S., Bracy D., Mattox S., Vesole D., Naucke S., Barlogie B. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood
   Google Scholar
• Tricot G., Jagannath S., Vesole D., Nelson J., Tindle S., Miller L., Cheson B., Crowley J., Barlogie B. Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588–596
   PubMed Web of Science ®Google Scholar
• Tricot G., Jagannath S., Vesole D., Crowley J., Barlogie B. Relapse of multiple myeloma after autologous transplantation: Survival after salvage therapy. Bone Marrow Transplant
   Google Scholar
• Bell J. B. G., Maitland J.A., Gore M., Millar B.C., et al. Increase in clonogenic tumour cells in bone marrow of patients with multiple myeloma treated with vincristine, doxorubicin, and methyl-prednisolone. Lancet 1988; 2: 931–933
   PubMed Web of Science ®Google Scholar
• Abdou N.I., Abdou N.L. The monoclonal nature of lymphocytes in multiple myeloma. Ann. Intern. Med. 1975; 83: 42–45
   PubMed Web of Science ®Google Scholar
• Mellstedt H., Hammarstrom S., Holm G. Monoclonal lymphocyte population in human plasma cell myeloma. Clin. Exp. Immunol. 1974; 17: 371–384
   PubMed Web of Science ®Google Scholar
• Bast E., Van Camp B., Reynaert P., Wiringa G., et al. Idiotypic peripheral blood lymphocytes in human monoclonal gam-mopathy. Clin. Exp. Immunol. 1982; 47: 677–682
   PubMed Web of Science ®Google Scholar
• Carmagnola A., Boccadoro M., Massaia M., Pileri A. The idiotypic specificities of lymphocytes in human monoclonal gammopathies: Analysis with the fluorescence activated cell sorter. Clin. Exp. Immunol. 1983; 51: 173–177
   PubMed Web of Science ®Google Scholar
• Berenson J., Wong R., Kim K., Brown N., et al. Evidence for peripheral blood B lymphocyte but not T lymphocyte involvement in multiple myeloma. Blood 1987; 70: 1550–1553
   PubMed Web of Science ®Google Scholar
• Vora A.J., Toh C.H., Peel J., Greaves M. Use of gran-ulocyte colony-stimulating factor (G-CSF) for mobilizing peripheral blood stem cells: Risk of mobilizing clonal myeloma cells in patients with bone marrow infiltration. Br. J. Haematol. 1994; 86: 180–182
   PubMed Web of Science ®Google Scholar
• Witzig T.E., Gertz M.A., Pineda A.A., Kyle R.A., Greipp P.R. Detection of monoclonal plasma cells in the peripheral blood stem cell harvests of patients with multiple myeloma. Br. J. Haematoi. 1995; 89: 640–642
   PubMed Web of Science ®Google Scholar
• Bird J.M., Bloxham D., Russell N.H., Samson D., Apperley J.F. Detection of clonally rearranged cells in PBSC harvests in multiple myeloma by immunoglobulin gene fingerprinting. Blood 1993; 82(Supp 11)265a
   Google Scholar
• Dreyfus F., Ribrag V., Leblond V., Ravaud P., Melle J., Quarre M.C., Pillier C., Boccaccio C., Varet B. Detection of malignant B cells in peripheral blood stem cell collections after chemotherapy in patients with multiple myeloma. Bone Marrow Transplant 1995; 15: 707–711
   PubMed Web of Science ®Google Scholar
• Belch A.R., Bergsagel P.L., Szczepek A., Lansdorp P., Pilarski L.M. CD34+ B cells in the blood of patients with multiple myeloma express clonotypic IgH sequences. Blood 1994; 84(Supp 11)385a
   Google Scholar
• Vescio R.A., Hong C.H., Cao J., Kim A., Schiller G.J., Lichtenstein A.K., Berenson R.J., Berenson J.R. The hematopoietic stem cell antigen CD34, is not expressed on the malignant cells in multiple myeloma. Blood 1994; 84: 3283–3290
   PubMed Web of Science ®Google Scholar
• Gazitt Y., Reading C.C., Hoffman R., Wickrema A., Vesole D., Jagannath S., Condino J., Lee B., Barlogie B., Tricot G. Purified CD34+Lin-Thy+ stem cells do not contain clonal myeloma cells. Blood 1995; 86: 381–389
   PubMed Web of Science ®Google Scholar
• Anderson K.C., Barut B.A., Ritz J., Freedman A.S., Takvorian T., Rabinowe S.N., Soiffer R., Heflin L., Coral F., Dear K., Mauch P., Nadler L.M. Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. Blood 1991; 77: 712–720
   PubMed Web of Science ®Google Scholar
• Reece D.E., Barnett M.J., Connors J.M., Klingemann H-G., O'Reilly S.E., Shepherd J.D., Sutherland H.J., Phillips G.L. Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hy-droperoxycyclophosphamide. Bone Marrow Transplant 1993; 11: 139–146
   PubMed Web of Science ®Google Scholar
• Schiller G., Vescio R., Freytes C., Spitzer G., Sahebi F., Lee M., Wu C.H., Cao J., Lee J.C., Hong C.H., Lichtenstein A., Lill M., Hall J., Berenson R., Berenson J. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 1995; 86: 390–397
   PubMed Web of Science ®Google Scholar
• Takishita M., Kosaka M., Goto T., Saito S. Cellular origin and extent of clonal involvement in multiple myeloma: Genetic and phenotypic studies. Br. J. Haematoi. 1994; 87: 735–742
   PubMed Web of Science ®Google Scholar
• Bergsagel P.L., Belch A.R., Pilarski L.M. The blood B cells and bone marrow plasma cells in a patient with multiple myeloma include cells with the same N-ras mutation. Blood 1994; 84(Supp 11)524a
   Google Scholar
• Murray L., Chen B., Galy A., Chen S., Tushinski R., Uchida N., Negrin R., Tricot G., Jagannath S., Vesole D., Barlogie B., Hoffman R., Tsukamoto A. Enrichment of human hematopoietic stem cell activity in the CD34+Thy-1+Lin-subpop-ulation from mobilized peripheral blood. Blood 1995; 85: 368–378
   PubMed Web of Science ®Google Scholar
• Gazitt Y., Tian E., Barlogie B., Reading C.C., Vesole D., Jagannath S., Schnell J., Hoffman R., Tricot G. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma following treatment with cyclophosphamide and GM-CSF, (submitted)
   Google Scholar
• Attal M., Stoppa A.M., Sotto J.J., Fuzibet G., Rossi J.F., Casassus P., Thyss A., Maisonneuve H., Facon T., Ifrah N., Payen C., Bataille R. High dose therapy in multiple myeloma: A prospective randomized study of the “Intergroupe Francais du Myelome” (IFM). Blood 1994; 84(Suppl 1)386a
   Google Scholar
• Alexanian R., Dimopoulos M.A., Hester J., Delasalle K., Champlin R. Early myeloablative therapy for multiple myeloma. Blood 1994; 84: 4278–4282
   PubMed Web of Science ®Google Scholar
• Alexanian R., Dimopoulos M., Smith T., Delasalle K., Barlogie B., Champlin R. Limited value of myeloablative therapy for late multiple myeloma. Blood 1994; 83: 512–516
   PubMed Web of Science ®Google Scholar
• Mandelli F., Avvisati G., Amadori S., Boccadoro M., Gernone A., Lauta V.M., Marmont F., Petrucci M.T., Tribalto M., Vegna M.L., Dammacco F., Pileri A. Maintenance treatment with recombinant interferon Alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N. Engl. J. Med. 1990; 322: 1430–1434
   PubMed Web of Science ®Google Scholar
• Cunningham D., Powles R., Malpas J.S., Milan S., Meldrum M., Viner C., Montes A., Hickish T., Nicolson M., Johnson P., Mansi J., Treleaven J., Raymond J., Gore M.E. A randomised trial of maintenance therapy with intron-A following high dose melphalan and ABMT in myeloma. Proc. ASCO 1993; 12: 1232
   Google Scholar
• Miller J.S., Arthur D.C., Litz C.E., Neglia J.P., Miller W.J., Weisdorf D.J. Myelodysplastic syndrome after autol-ogous bone marrow transplantation: An additional late complication of curative cancer therapy. Blood 1994; 83: 3780–3786
   PubMed Web of Science ®Google Scholar
• Traweek S.T., Slovak M.L., Nademanee A.P., Brynes R.K., Niland J.C., Forman S.J. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lym-phoma. Blood 1994; 84: 957–963
   PubMed Web of Science ®Google Scholar
• Darrington D.L., Vose J.M., Anderson J.R., Bierman P.J., Bishop M.R., Chan W.C., Morris M.E., Reed E.C., Sanger W.G., Tarantolo S.R., Weisenburger D.D., Kessinger A., Armitage J.O. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J. Clin. Oncol. 1994; 12: 2527–2534
   PubMed Web of Science ®Google Scholar
• Stone R.M., Neuberg D., Soiffer R., Takvorian T., Whelan M., Rabinowe S.N., Aster J.C., Leavitt P., Mauch P., Freedman A.S., Nadler L.M. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J. Clin. Oncol. 1994; 12: 2535–2542
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J., Ersboll J., Sorensen H.M., Keiding N., Larsen S.O., Philip P., Larsen M.S., Schultz H., Nissen N.I. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lym-phomas. Ann. Int. Med. 1985; 103: 195–200
   PubMed Web of Science ®Google Scholar
• Levine E.G., Bloomfield C.D. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Sem. Oncol. 1992; 19: 47–84
   PubMed Web of Science ®Google Scholar
• Sharp J.G., Joshi S.S., Armitage J.O., Bierman P., Coccia P.F., Harrington D.S., Kessinger A., Crouse D.A., Mann S.L., Weisenburger D.D. Significance of detection of occult non-Hodgkin's lymphoma in histologically univolved bone marrow by a culture technique. Blood 1992; 79: 1074–1080
   PubMed Web of Science ®Google Scholar
• Brenner M.K., Rill D.R., Moen R.C., Krance R.A., Mirro J., Anderson W.F., Ihle J.N. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85–86
   PubMed Web of Science ®Google Scholar
• Meloni G., Foa R., Vignetti M., Guarini A., Fenu S., Tosti S., Tos A.G., Mandelli F. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 1994; 84: 2158–2163
   PubMed Web of Science ®Google Scholar
• Hoover R.G., Lary C., Page R., et al. Autoregulatory circuits in myeloma: Tumor cell cytotoxicity mediated by soluble CD 16. J. Clin. Invest.
   Web of Science ®Google Scholar
• Stevenson F.K., Bell A.J., Cusack R., Hamblin T.J., Slade C.J., Spellerberg M.B., Stevenson G.T. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood 1991; 77: 1071–1079
   PubMed Web of Science ®Google Scholar
• Grossbard M.L., Gribben J.G., Freedman A.S., Lambert J.M., Kinsella J., Rabinowe S.N., Eliseo L., Taylor J.A., Blattler W.A., Epstein C.L., Nadler L.M. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood 1993; 81: 2263–2271
   PubMed Web of Science ®Google Scholar
• Calabretta B. Inhibition of protooncogene expression by an-tisense oligodeoxynucleotides: Biological and therapeutic implications. Cancer Res. 1991; 51: 4505–4510
   PubMed Web of Science ®Google Scholar
• Cuthbert J.A., Lipsky P.E. Suppression of the proliferation of Ras-transformed cells by fluoromevalonate, an inhibitor of mevalonate metabolism. Cancer Res. 1995; 55: 1732–1740
   PubMed Web of Science ®Google Scholar
• Mizutani Y., Bonavida B., Koishihara Y., Akamatsu K., Ohsugi Y., Yoshida O. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum (II) by anti-Interleukin 6 monoclonal antibody or anti-Interleukin 6 receptor monoclonal antibody. Cancer Res. 1995; 55: 590–596
   PubMed Web of Science ®Google Scholar